Search

Background: Interventional magnetic resonance imaging (MRI) at 3T benefits from higher spatial and temporal resolution, but artifacts of metallic instruments are often larger and may obscure target structures., Purpose: To test that compressed sensing (CS) slice-encoding metal artifact correction (SEMAC) is feasible for 3T interventional MRI and affords more accurate instrument visualization than turbo spin echo (TSE) and gradient echo (GRE) techniques, and facilitates faster data acquisition than conventional SEMAC., Study Type: Prospective., Phantom and Subjects: Cadaveric animal and 20 human subjects., Field Strength/sequence: TSE (acquisition time 31 sec), GRE (28-33 sec), SEMAC (128 sec), and CS-SEMAC (57 sec) pulse sequences were evaluated at 3T., Assessment: Artifact width and length, signal-to-noise (SNR), and contrast-to-noise (CNR) ratios of 14-22G MR-conditional needles were measured in a phantom. Subsequently, high-bandwidth TSE and CS-SEMAC sequences were assessed in vivo with 20 patient procedures for the size of the metal artifact, image sharpness, image noise, motion artifacts, image contrast, and target, instrument, and structural visibility., Statistical Tests: Repeated-measures-analysis-of-variances and Mann-Whitney U-tests were applied. P ≤ 0.05 was considered statistically significant., Results: CS-SEMAC and SEMAC created the smallest needle artifact widths (3.2-3.3 ± 0.4 mm, P = 1.0), whereas GRE showed the largest needle artifact widths (8.5-8.6 ± 0.4 mm) (P < 0.001). The artifact width difference between high-bandwidth TSE and CS-SEMAC was 0.8 ± 0.6 mm (P < 0.01). SEMAC and CS-SEMAC created the lowest average needle tip errors (0.3-0.4 ± 0.1 mm, P = 1.0). The average tip error difference between high-bandwidth TSE and SEMAC/CS-SEMAC was 2.0 ± 1.7 mm (P < 0.01). SNR and CNR were similar on TSE, SEMAC, and CS-SEMAC, and lowest on GRE. CS-SEMAC yielded smaller artifacts, less noise, less motion, and better instrument visibility (P < 0.001); high-bandwidth TSE showed better sharpness (P < 0.001) and targets visibility (P = 0.007); whereas image contrast (P = 0.273) and structural visibility (P = 0.1) were similar., Data Conclusion: CS-SEMAC is feasible for interventional MRI at 3T, visualizes instruments with higher accuracy than high-bandwidth TSE and GRE, and can be acquired 55% faster than conventional SEMAC., Level of Evidence: 2 Technical Efficacy: Stage 6 J. Magn. Reson. Imaging 2018;47:1306-1315., (© 2017 International Society for Magnetic Resonance in Medicine.)

Purpose: To demonstrate the feasibility, safety, and effectiveness of image-guided sclerotherapy of low-flow vascular malformations using a 1.5 Tesla (T) MR scanner with real-time imaging capability and in-suite fluoroscopy., Materials and Methods: Thirty-three procedures were performed with real-time 1.5T MR-guidance on 22 patients with a vascular malformation in the neck (n = 2), chest (n = 6), abdomen and pelvis (n = 15), and extremities (n = 11). Quantitative analysis was performed for changes in (a) planning time, (b) targeting time (interval between needle skin puncture and lesion access), (c) intervention time (interval between needle skin puncture and needle removal), and (d) total procedure time. Qualitative analysis was performed for (a) success of therapy and (b) occurrence of complications., Results: Technical success was achieved in 29 of 33 procedures. The average planning time did not significantly change between the first seven procedures and the last seven procedures (P = 0.447). The average targeting time decreased by 0:24:45 (hours:minutes:seconds) (P = 0.043), the average intervention time decreased by 0:26:58 (P = 0.022), and the average procedure time decreased by 0:28:41 (P = 0.046) when comparing the first seven procedures and the last seven procedures. Overall, there was an improvement in the patients' predominant symptoms following 82% of procedures, including a significant decrease in average pain following therapy (P < 0.001). There was a minor complication rate of 3% with no major complications., Conclusion: MR-guided percutaneous sclerotherapy seems to be a safe, effective, and versatile technique for treating low-flow vascular malformations., Level of Evidence: 3 J. Magn. Reson. Imaging 2017;45:1154-1162., (© 2016 International Society for Magnetic Resonance in Medicine.)

Purpose: Image-guided treatment of low-flow vascular (venous or lymphatic) malformations presents a challenging visualization problem, regardless of the imaging modality being used for guidance. The purpose of this study was to employ a new magnetic resonance imaging (MRI) sequence, T2 -weighted interrupted balanced steady-state free precession (T2 W-iSSFP), for real-time image guidance of needle insertion., Materials and Methods: T2 W-iSSFP uses variable flip angle balanced steady-state free precession (bSSFP, a.k.a. SSFP) to establish T2 -weighting and fat suppression. Swine (n = 3) and patients (n = 4, three female, all with venous malformations) were enrolled in the assessment. T2 -weighted turbo spin echo (T2 -TSE) with spectral adiabatic inversion recovery (SPAIR), SPAIR-T2 -TSE or T2 -TSE for short, was used as the reference. T2 -weighted half Fourier acquired single shot turbo spin echo (T2 -HASTE) with SPAIR (SPAIR-T2 -HASTE, T2 -HASTE for short), fat saturated bSSFP (FS-SSFP), and T2 W-iSSFP were imaged. Numeric metrics, namely, contrast-to-noise ratio (CNR) efficiency (CNR divided by the square root of acquisition time) and local sharpness (the reciprocal of edge width), were used to assess image quality. MR-guided sclerotherapy was performed on the same patients using real-time T2 W-iSSFP to guide needle insertion., Results: Comparing the visualization of needles in the images of swine, the local sharpness (mm(-1) ) was: 0.21 ± 0.06 (T2 -HASTE), 0.48 ± 0.02 (FS-SSFP), and 0.49 ± 0.03 (T2 W-iSSFP). T2 W-iSSFP is higher than T2 -HASTE (P < 0.001). For the patient images, their CNR efficiencies were: 797 ± 66 (T2 -HASTE), 281 ± 44 (FS-SSFP), and 860 ± 29 (T2 W-iSSFP). T2 W-iSSFP is higher than FS-SSFP (P < 0.02). The frame rate of T2 W-iSSFP was 2.5-3.5 frames per second. All MR-guided sclerotherapy procedures were successful, with all needles (six punctures) placed in the targets., Conclusion: T2 W-iSSFP provides effective lesion identification and needle visualization. This new pulse sequence can be used for MR-guided sclerotherapy of low-flow vascular malformations. It may have potential use in other MR-guided procedures where heavily T2 -weighted real-time images are needed., (© 2014 Wiley Periodicals, Inc.)

Purpose: To develop and evaluate software-based methods for improving the workflow of magnetic resonance (MR)-guided percutaneous interventions., Materials and Methods: A set of methods was developed that allows the user to: 1) plan an entire procedure, 2) directly apply this plan to skin entry site localization without further imaging, and 3) place a needle under real-time MR guidance with automatic alignment of three orthogonal slices along a planned trajectory with preference to the principal patient axes. To validate targeting accuracy and time, phantom experiments (96 targets) and in vivo paraspinal and kidney needle punctures in two pigs (55 targets) were performed. The influence of trajectory obliquity, level of experience, and organ motion on targeting accuracy and time was analyzed., Results: Mean targeting error was 1.8 ± 0.9 mm (in vitro) and 2.9 ± 1.0 mm (in vivo) in all directions. No statistically significant differences in targeting accuracy between single- and double-oblique trajectories, novice and expert users, or paraspinal and kidney punctures were observed. The average time (in vivo) from trajectory planning to verification of accurate needle placement was 6 minutes., Conclusion: The developed methods allow for accurate needle placement along complex trajectories and are anticipated to reduce table time for MR-guided percutaneous needle interventions., (Copyright © 2013 Wiley Periodicals, Inc.)

Purpose: To investigate the utility of inversion recovery with ON-resonant water suppression (IRON) to create positive signal in normal lymph nodes after injection of superparamagnetic nanoparticles., Materials and Methods: Experiments were conducted on six rabbits, which received a single bolus injection of 80 mumol Fe/kg monocrystalline iron oxide nanoparticle (MION-47). Magnetic resonance imaging (MRI) was performed at baseline, 1 day, and 3 days after MION-47 injection using conventional T(1)- and T(2)*-weighted sequences and IRON. Contrast-to-noise ratios (CNR) were measured in blood and in paraaortic lymph nodes., Results: On T(2)*-weighted images, as expected, signal attenuation was observed in areas of paraaortic lymph nodes after MION-47 injection. However, using IRON the paraaortic lymph nodes exhibited very high contrast enhancement, which remained 3 days after injection. CNR with IRON was 2.2 +/- 0.8 at baseline, increased markedly 1 day after injection (23.5 +/- 5.4, P < 0.01 vs. baseline), and remained high after 3 days (21.8 +/- 5.7, *P < 0.01 vs. baseline). CNR was also high in blood 1 day after injection (42.7 +/- 7.2 vs. 1.8 +/- 0.7 at baseline, P < 0.01) but approached baseline after 3 days (1.9 +/- 1.4, P = NS vs. baseline)., Conclusion: IRON in conjunction with superparamagnetic nanoparticles can be used to perform 'positive contrast' MR-lymphography, particularly 3 days after injection of the contrast agent, when signal is no longer visible within blood vessels. The proposed method may have potential as an adjunct for nodal staging in cancer screening., ((c) 2008 Wiley-Liss, Inc.)

With the recent advances in magnetic resonance (MR) labeling of cellular therapeutics, it is natural that interventional MRI techniques for targeting would be developed. This review provides an overview of the current methods of stem cell labeling and the challenges that are created with respect to interventional MRI administration. In particular, stem cell therapies will require specialized, MR-compatible devices as well as integration of graphical user interfaces with pulse sequences designed for interactive, real-time delivery in many organs. Specific applications that are being developed will be reviewed as well as strategies for future translation to the clinical realm., ((Copyright) 2008 Wiley-Liss, Inc.)